Penicillin Therapeutic Drug Monitoring in the Treatment of Infectious Syphilis.

NCT01540227 | Terminated

• 1 other identifier: CTN PT-011
• Study Type: observational
• Target: 25
• Locations: 1 country
• Sites: 3

Brief Summary

Syphilis is a sexually transmitted infection that causes genital sores and rash, but in some circumstances may result in more severe and unexpected symptoms. These severe symptoms could include eye infections, meningitis (infection of the membranes covering the brain and spinal cord), and liver infection. If not properly treated, syphilis can also lead to heart problems and dementia (a decline in reasoning, memory and other mental abilities) years down the road. There has been an increase in the number of reported cases of syphilis in North America, Europe, and Australia over the past decade. The number of new syphilis infections in Canada has increased roughly 10-fold over the past 10 years. Since 1943, the antibiotic penicillin has been used to treat syphilis; however, very little information has been gathered to determine the proper dose of penicillin or appropriate duration of treatment. Added to this, several studies have shown that the recommended dose of penicillin fails to cure syphilis in 20-30% of patients. Since the number of people infected with syphilis is increasing, and since syphilis has the potential to cause serious disease, the investigators need better information on how to treat syphilis effectively. This study aims to determine whether the current dose of penicillin recommended to treat syphilis is sufficient to cure the infection. Specifically the investigators will try to determine whether the amount of penicillin in your blood 3 and 7 days after receiving treatment for syphilis is sufficient to cure the infection as demonstrated by a blood test 6 or 12 months from now. This study is a multi-centered trial based in Ottawa but with centers recruiting both in Montreal and Toronto. A total of 120 participants with syphilis will be recruited into this study. The treatment you will receive for syphilis in this study does not differ from that you would receive normally; the investigators are only observing the levels of penicillin in your blood and relating them with the outcome of treatment.

Conditions

Syphilis; Primary Syphilis; Secondary Syphilis; Early-Latent Syphilis

Keywords

Syphilis; Penicillin

Outcome Measures

Primary Outcomes (1)

• Penicillin and Treatment Failure

  To determine if serum penicillin concentrations measured at days 3 and 7 post-treatment differ between those who achieve successful treatment of infectious syphilis versus those who experience treatment failure.

  6 months post-treatment

Secondary Outcomes (1)

• HIV and Treatment Failure

  6 months post-treatment

Study Arms (1)

Syphilis Patients

Individuals presenting for treatment of primary, secondary or early latent syphilis at the Ottawa Hospital Immunodeficiency Clinic, the Ottawa Sexual Health Clinic or its satellite GayZone, the Montreal Chest Institute Immunodeficiency Clinic, or the Toronto General Immunodeficiency Clinic will be invited by their attending health care worker to participate in this study. Only patients presenting for and requiring treatment of infectious syphilis will be asked to participate.

Drug: Regular Treatment for Syphilis

Interventions

Regular Treatment for Syphilis DRUG

Drug: Benzathine Penicillin G (Bicillin) Dose: 2.4 million units Mode of Administration: intramuscular injection Duration of Treatment: one dose Health Canada approved indication: Yes

Syphilis Patients

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Individuals presenting for treatment of primary, secondary or early latent syphilis will be invited by their attending health care worker to participate in this study. Only patients presenting for and requiring treatment of infectious syphilis will be asked to participate.

You may qualify if:

• Participants must meet all of the following criteria to be considered eligible for entry into the study:
• At least 18 years of age
• Presenting with clinical signs of either primary or secondary syphilis; or with early latent syphilis and documented negative serology within the past 12 months.
• Positive syphilis serology (reactive CMIA and TP-PA) with a defined RPR titer at the time of diagnosis and enrolment
• Able to provide informed consent
• Able to communicate in either English of French
• Able to return for follow-up

You may not qualify if:

• Participants are not eligible to participate in the study if any of the following conditions are met:
• Diagnosis of late latent syphilis, tertiary syphilis, or syphilis of unknown duration
• Allergy to penicillin
• Diagnosis of neurosyphilis requiring treatment with intravenous penicillin
• Treatment with doxycycline or ceftriaxone
• Treatment with more than one intramuscular dose of benzathine penicillin G
• Treatment with any antibiotics within the 6 weeks prior to enrolment
• Pregnant or breastfeeding
• Any immune modulating therapy
• Patient is unable or unwilling to return for blood sampling at 3 and 7 days post treatment

Sponsors & Collaborators

• Ottawa Hospital Research Institute: lead
• CIHR Canadian HIV Trials Network: collaborator

Study Sites (3)

The Ottawa Hospital

Ottawa, Ontario, K1H 8L6, Canada

Location

Ottawa Sexual Health Clinic/GayZone

Ottawa, Ontario, K1N 5P7, Canada

Location

Toronto General Hospital

Toronto, Ontario, M5G 2C4, Canada

Location

MeSH Terms

Conditions

Syphilis; Syphilis, primary; Syphilis, secondary

Condition Hierarchy (Ancestors)

Treponemal Infections; Spirochaetales Infections; Gram-Negative Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Infections; Sexually Transmitted Diseases, Bacterial; Sexually Transmitted Diseases; Communicable Diseases; Genital Diseases; Urogenital Diseases

Study Officials

• Paul A MacPherson, MD/PhD

  The Ottawa Hospital/The University of Ottawa/OHRI

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Physician/Scientist

Study Record Dates

• First Submitted: February 16, 2012
• First Posted: February 28, 2012
• Study Start: September 1, 2011
• Primary Completion: November 10, 2016
• Study Completion: November 10, 2016
• Last Updated: April 6, 2018

Record last verified: 2018-04

Locations

CA (3)